v3.26.1
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
PSUs
Class A Common Stock
Class A Common Stock
PSUs
Additional Paid-In Capital
Additional Paid-In Capital
PSUs
Accumulated Other Comprehensive Loss
Retained Earnings (Accumulated Deficit)
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2024 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2024 $ 190,173                
Mezzanine Equity                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 38,627                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2025 175,000                
Series A preferred stock , ending balance at Jun. 30, 2025 $ 228,800                
Beginning balance (in shares) at Dec. 31, 2024     116,576,000            
Beginning balance at Dec. 31, 2024 1,001,259   $ 1,166   $ 1,803,786   $ (1,753) $ (780,817) $ (21,123)
Shareholders’ Equity                  
Stock-based compensation expense 22,661       22,661        
Restricted stock units vested, net of shares withheld for taxes (in shares)     585,000            
Restricted stock units vested, net of shares withheld for taxes (2,799)   $ 6   (2,805)        
Performance stock units vested, net of shares withheld for taxes (in shares)       312,000          
Performance stock units vested, net of shares withheld for taxes   $ (1,822)   $ 3   $ (1,825)      
Foreign currency translation adjustment 46           46    
Net loss attributable to common shareholders of Evolent Health, Inc. (123,340)       (38,825)     (84,515)  
Ending balance (in shares) at Jun. 30, 2025     117,473,000            
Ending balance at Jun. 30, 2025 $ 896,005   $ 1,175   1,782,992   (1,707) (865,332) (21,123)
Series A preferred stock , beginning balance (in shares) at Mar. 31, 2025 175,000                
Series A preferred stock , beginning balance at Mar. 31, 2025 $ 193,228                
Mezzanine Equity                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 35,572                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2025 175,000                
Series A preferred stock , ending balance at Jun. 30, 2025 $ 228,800                
Beginning balance (in shares) at Mar. 31, 2025     117,398,000            
Beginning balance at Mar. 31, 2025 935,521   $ 1,174   1,802,634   (1,729) (845,435) (21,123)
Shareholders’ Equity                  
Stock-based compensation expense 11,580       11,580        
Restricted stock units vested, net of shares withheld for taxes (in shares)     75,000            
Restricted stock units vested, net of shares withheld for taxes (28)   $ 1   (29)        
Foreign currency translation adjustment 22           22    
Net loss attributable to common shareholders of Evolent Health, Inc. (51,090)       (31,193)     (19,897)  
Ending balance (in shares) at Jun. 30, 2025     117,473,000            
Ending balance at Jun. 30, 2025 $ 896,005   $ 1,175   1,782,992   (1,707) (865,332) (21,123)
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2025 0                
Series A preferred stock , beginning balance at Dec. 31, 2025 $ 0                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2026 0                
Series A preferred stock , ending balance at Jun. 30, 2026 $ 0                
Beginning balance (in shares) at Dec. 31, 2025 117,603,806   117,604,000            
Beginning balance at Dec. 31, 2025 $ 415,194   $ 1,176   1,793,398   (2,624) (1,315,327) (61,429)
Shareholders’ Equity                  
Stock-based compensation expense 25,850       25,850        
Restricted stock units vested, net of shares withheld for taxes (in shares)     951,000            
Restricted stock units vested, net of shares withheld for taxes (1,586)   $ 10   (1,596)        
Performance stock units vested, net of shares withheld for taxes (in shares)       101,000          
Performance stock units vested, net of shares withheld for taxes   $ (237)   $ 1   $ (238)      
Foreign currency translation adjustment (1,002)           (1,002)    
Net loss attributable to common shareholders of Evolent Health, Inc. $ (54,996)             (54,996)  
Ending balance (in shares) at Jun. 30, 2026 118,656,443   118,656,000            
Ending balance at Jun. 30, 2026 $ 383,223   $ 1,187   1,817,414   (3,626) (1,370,323) (61,429)
Series A preferred stock , beginning balance (in shares) at Mar. 31, 2026 0                
Series A preferred stock , beginning balance at Mar. 31, 2026 $ 0                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2026 0                
Series A preferred stock , ending balance at Jun. 30, 2026 $ 0                
Beginning balance (in shares) at Mar. 31, 2026     118,449,000            
Beginning balance at Mar. 31, 2026 396,393   $ 1,185   1,802,222   (3,626) (1,341,959) (61,429)
Shareholders’ Equity                  
Stock-based compensation expense 15,201       15,201        
Restricted stock units vested, net of shares withheld for taxes (in shares)     207,000            
Restricted stock units vested, net of shares withheld for taxes (7)   $ 2   (9)        
Foreign currency translation adjustment 0                
Net loss attributable to common shareholders of Evolent Health, Inc. $ (28,364)             (28,364)  
Ending balance (in shares) at Jun. 30, 2026 118,656,443   118,656,000            
Ending balance at Jun. 30, 2026 $ 383,223   $ 1,187   $ 1,817,414   $ (3,626) $ (1,370,323) $ (61,429)